Treatment of stocks of herpes simplex virus type 1 (HSV‐1) and type 2 (HSV‐2) with the chemical carcinogen 4‐nitroquinoline 1‐oxide (NQO) resulted in inactivation of virus infectivity at rates which were directly dependent on the concentration of NQO and interval of exposure to NQO. HSV‐1 strains were more sensitive than HSV‐2 strains to inactivation by NQO, although survival curves of both HSV types were multicomponent. Exposure of HSV‐2 to a related group of chemicals suggested that the structural specificity required for inactivation of this virus was similar to that established by previous in vivo carcinogenicity tests.
- 4‐nitroquinoline 1‐oxide
- herpes simplex virus
ASJC Scopus subject areas
- Health, Toxicology and Mutagenesis